Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that seem undruggable using the traditional drug...
Guardado en:
Autores principales: | , |
---|---|
Formato: | Libro |
Publicado: |
MDPI AG,
2023-03-01T00:00:00Z.
|
Materias: | |
Acceso en línea: | Connect to this object online. |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Clasificación: |
A1234.567 |
---|---|
Copia 1 | Disponible |